
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a report released on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.96) per share for the year, up from their prior estimate of ($0.98). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.23) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at $0.14 EPS.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.03.
Read Our Latest Stock Report on EPRX
Eupraxia Pharmaceuticals Stock Up 4.4%
Shares of Eupraxia Pharmaceuticals stock traded up $0.34 on Friday, hitting $8.15. The company had a trading volume of 777,240 shares, compared to its average volume of 579,571. The stock has a 50-day moving average of $7.64 and a 200-day moving average of $7.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.25 and a quick ratio of 16.00. Eupraxia Pharmaceuticals has a twelve month low of $5.63 and a twelve month high of $9.32. The firm has a market capitalization of $548.01 million, a P/E ratio of -7.69 and a beta of 1.04.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC boosted its stake in shares of Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after buying an additional 1,289,005 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $6,851,000. Seven Fleet Capital Management LP bought a new stake in Eupraxia Pharmaceuticals during the first quarter worth about $5,137,000. Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals during the first quarter valued at approximately $5,068,000. Finally, Rubric Capital Management LP acquired a new position in Eupraxia Pharmaceuticals during the first quarter valued at approximately $5,004,000.
Eupraxia Pharmaceuticals News Summary
Investors following EPRX have been watching these news items:
- Positive Sentiment: Cantor Fitzgerald and Oppenheimer each initiated or reiterated a Buy view on EPRX, adding to positive analyst coverage. Cantor Fitzgerald Buy rating Oppenheimer Buy rating
- Neutral Sentiment: Interim results from Eupraxia’s Phase 2b eosinophilic esophagitis (EoE) trial are expected in December, creating a key upcoming clinical catalyst. Q3 results and trial update timing
- Negative Sentiment: HC Wainwright lowered its fiscal 2027 and 2029 EPS forecasts, while the company reported a wider third-quarter loss—risks that temper the positive analyst news. Analyst estimates Quarterly loss report
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
- 3 GARP Plays That Could Offer a Better Balance as Markets Turn Volatile
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
